The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2017
Population-based study on antenatal corticosteroid treatment in preterm small for gestational age and non-small for gestational age twin infants.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riskin-Mashiah Shlomit, Reichman Brian, Bader David, Kugelman Amir, Boyko Valentina, Lerner-Geva Liat, Riskin Arieh, Israel Neonatal Network
Аннотация
OBJECTIVES: To assess the associations between antenatal corticosteroid use (ACU), mortality and severe morbidities in preterm, twin neonates and compare these between small for gestational age (SGA) and non-SGA twins.
MATERIALS AND METHODS: Population-based study using data collected by the Israel National Very Low Birth Weight infant database from 1995 to 2012, comprising twin infants of 24-31 weeks' gestation, without major malformations. Univariate and multivariable logistic regression analyses were performed.
RESULTS: Among the 6195 study twin infants, 784 were SGA. Among SGA neonates, ACU were associated with decreased mortality (23.9% vs. 39.2%, p < 0.0001) and composite adverse outcome including mortality or severe neonatal morbidity (43.8% vs. 56.8%, p = 0.0015), similar to the effect in non-SGA neonates (mortality 13.0% vs. 24.5%, p < 0.0001; composite outcome 34.2% vs. 44.8%, p < 0.0001). In the multivariable logistic regression analyses, ACU were associated with an almost 50% reduced mortality risk among SGA twin neonates (OR = 0.52, 95% CI 0.31-0.88) similar to the effect in non-SGA twin neonates (OR = 0.56, 95% CI 0.45-0.70), Pinteraction = 0.69. Composite adverse outcome risk was also reduced in SGA (OR = 0.78, 95% CI 0.50-1.23) and non-SGA groups (OR = 0.78, 95% CI 0.65-0.95), Pinteraction = 0.95.
CONCLUSIONS: ACU should be considered in all mothers with twin gestation, at risk for preterm delivery at 24-31 weeks, in order to improve perinatal outcome.
MATERIALS AND METHODS: Population-based study using data collected by the Israel National Very Low Birth Weight infant database from 1995 to 2012, comprising twin infants of 24-31 weeks' gestation, without major malformations. Univariate and multivariable logistic regression analyses were performed.
RESULTS: Among the 6195 study twin infants, 784 were SGA. Among SGA neonates, ACU were associated with decreased mortality (23.9% vs. 39.2%, p < 0.0001) and composite adverse outcome including mortality or severe neonatal morbidity (43.8% vs. 56.8%, p = 0.0015), similar to the effect in non-SGA neonates (mortality 13.0% vs. 24.5%, p < 0.0001; composite outcome 34.2% vs. 44.8%, p < 0.0001). In the multivariable logistic regression analyses, ACU were associated with an almost 50% reduced mortality risk among SGA twin neonates (OR = 0.52, 95% CI 0.31-0.88) similar to the effect in non-SGA twin neonates (OR = 0.56, 95% CI 0.45-0.70), Pinteraction = 0.69. Composite adverse outcome risk was also reduced in SGA (OR = 0.78, 95% CI 0.50-1.23) and non-SGA groups (OR = 0.78, 95% CI 0.65-0.95), Pinteraction = 0.95.
CONCLUSIONS: ACU should be considered in all mothers with twin gestation, at risk for preterm delivery at 24-31 weeks, in order to improve perinatal outcome.